Healthcare
Edesa Biotech, Inc.(EDSA)
Live Price
Offline$7.35
+6.83% today
1Y Change
+280.10%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $130.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +34.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Edesa Biotech, Inc. (EDSA) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $7.35 and up 280.1% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +34.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +34.2%, free cash flow -49.7% with operating margin 0.0% and ROIC -59.9%. Stock Foundry combines EDSA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +34.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -12.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +14.8% | -9.9% | -60.7% |
2026 Feb 13, 2026 | +0.0% | +1.0% | -11.8% | +402.0% |
2025 Dec 12, 2025 | -18.5% | -16.1% | -14.9% | -16.7% |
Benchmark Edge
EDSA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EDSA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EDSA Max Drawdown
-72.98%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EDSA and SPY.
Company Overview
Edesa Biotech, Inc.
NASDAQ Capital Market
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
- Leadership
- Pardeep Nijhawan
- IPO Date
- Jun 21, 2010
- Employees
- 16
- Street Address
- 100 Spy Court
- Mailing
- Markham, ON, L3R 5H6
- Region
- Markham, ON, CA
- Reporting Currency
- USD
- Investor Line
- 289-800-9600
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 8.8
Growth
- Revenue
- 0.0%
- EPS
- +34.2%
- Free Cash Flow
- -49.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -55.8%
- ROIC
- -59.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 16.82
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.